{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T22:20:45Z","timestamp":1780957245957,"version":"3.54.1"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100011070","name":"Research Opportunities Initiative, University of North Carolina","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005562","name":"North Carolina Biotechnology Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005562","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009744","name":"Eshelman Institute for Innovation, University of North Carolina at Chapel Hill","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009744","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000008","name":"David and Lucile Packard Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000008","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008615","name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.nano.2019.102076","type":"journal-article","created":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T11:28:51Z","timestamp":1565004531000},"page":"102076","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Pretargeted delivery of PEG-coated drug carriers to breast tumors using multivalent, bispecific antibody against polyethylene glycol and HER2"],"prefix":"10.1016","volume":"21","author":[{"given":"Christina L.","family":"Parker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan D.","family":"McSweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T.","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Wadsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Zamboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel K.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nano.2019.102076_bb0005","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.addr.2010.04.009","article-title":"The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect","volume":"63","author":"Fang","year":"2011","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.nano.2019.102076_bb0010","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7150\/thno.7193","article-title":"Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target?","volume":"4","author":"Kobayashi","year":"2014","journal-title":"Theranostics"},{"key":"10.1016\/j.nano.2019.102076_bb0015","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.addr.2010.03.011","article-title":"Tumor delivery of macromolecular drugs based on the EPR effect","volume":"63","author":"Torchilin","year":"2011","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.nano.2019.102076_bb0020","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.addr.2010.04.009","article-title":"The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect","volume":"63","author":"Fang","year":"2011","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.nano.2019.102076_bb0025","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7150\/thno.7193","article-title":"Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target?","volume":"4","author":"Kobayashi","year":"2013","journal-title":"Theranostics"},{"key":"10.1016\/j.nano.2019.102076_bb0030","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.addr.2010.03.011","article-title":"Tumor delivery of macromolecular drugs based on the EPR effect","volume":"63","author":"Torchilin","year":"2011","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.nano.2019.102076_bb0035","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-642-00477-3_1","article-title":"Passive and active drug targeting: drug delivery to tumors as an example","volume":"197","author":"Torchilin","year":"2010","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.nano.2019.102076_bb0040","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.addr.2013.11.009","article-title":"Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology","volume":"66","author":"Bertrand","year":"2014","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.nano.2019.102076_bb0045","doi-asserted-by":"crossref","unstructured":"Torchilin VP. Passive and Active Drug Targeting: Drug Delivery to Tumors as an Example. In: Handbook of Experimental Pharmacology. Springer, Berlin, Heidelberg, pp. 3\u201353.","DOI":"10.1007\/978-3-642-00477-3_1"},{"key":"10.1016\/j.nano.2019.102076_bb0050","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s00432-014-1767-3","article-title":"Cancer active targeting by nanoparticles: a comprehensive review of literature","volume":"141","author":"Bazak","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.nano.2019.102076_bb0055","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc903","article-title":"Ligand-targeted therapeutics in anticancer therapy","volume":"2","author":"Allen","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.nano.2019.102076_bb0060","doi-asserted-by":"crossref","first-page":"6371","DOI":"10.1021\/acs.nanolett.5b01362","article-title":"Targeted PRINT hydrogels: the role of nanoparticle size and ligand density on cell association, biodistribution, and tumor accumulation","volume":"15","author":"Reuter","year":"2015","journal-title":"Nano Lett"},{"key":"10.1016\/j.nano.2019.102076_bb0065","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.nano.2012.05.015","article-title":"Effect of ligand density, receptor density, and nanoparticle size on cell targeting","volume":"9","author":"Elias","year":"2013","journal-title":"Nanomedicine Nanotechnology, Biol Med"},{"key":"10.1016\/j.nano.2019.102076_bb0070","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1073\/pnas.0711714105","article-title":"Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers","volume":"105","author":"Gu","year":"2008","journal-title":"PNAS"},{"key":"10.1016\/j.nano.2019.102076_bb0075","doi-asserted-by":"crossref","first-page":"6560","DOI":"10.2174\/1381612811319370002","article-title":"Mechanisms for targeted delivery of nanoparticles in cancer","volume":"19","author":"Beech","year":"2013","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.nano.2019.102076_bb0080","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/jps.22342","article-title":"Controlling ligand surface density optimizes nanoparticle binding to ICAM-1","volume":"100","author":"Fakhari","year":"2011","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.nano.2019.102076_bb0085","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1039\/c2ra01168a","article-title":"Ligand density and clustering effects on endocytosis of folate modified nanoparticles","volume":"2","author":"Moradi","year":"2012","journal-title":"RSC Adv"},{"key":"10.1016\/j.nano.2019.102076_bb0090","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1126\/science.1226338","article-title":"Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities","volume":"338","author":"Cheng","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.nano.2019.102076_bb0095","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.jconrel.2015.09.040","article-title":"Addressing challenges of heterogeneous tumor treatment through bispecific protein-mediated pretargeted drug delivery","volume":"220","author":"Yang","year":"2015","journal-title":"J Control Release"},{"key":"10.1016\/j.nano.2019.102076_bb0100","doi-asserted-by":"crossref","first-page":"6732","DOI":"10.1158\/0008-5472.CAN-05-4199","article-title":"Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models","volume":"66","author":"Kirpotin","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.nano.2019.102076_bb0105","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jconrel.2011.06.001","article-title":"Targeted drug delivery to tumors: myths, reality and possibility","volume":"153","author":"Bae","year":"2011","journal-title":"J Control Release"},{"key":"10.1016\/j.nano.2019.102076_bb0110","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1021\/bc020089t","article-title":"Folate-liposome-mediated antisense oligodeoxynucleotide targeting to Cancer cells: evaluation in vitro and in vivo","volume":"14","author":"Leamon","year":"2003","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nano.2019.102076_bb0115","doi-asserted-by":"crossref","first-page":"6415","DOI":"10.1039\/C5CS00784D","article-title":"New insights into the pretargeting approach to image and treat tumours","volume":"45","author":"Patra","year":"2016","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.nano.2019.102076_bb0120","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nrc3925","article-title":"Radioimmunotherapy of human tumours","volume":"15","author":"Larson","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.nano.2019.102076_bb0125","first-page":"15507","article-title":"Burnouf P-A, Chuang K-H, et al","volume":"8","author":"Su","year":"2017","journal-title":"Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapy Nat Commun"},{"key":"10.1016\/j.nano.2019.102076_bb0130","doi-asserted-by":"crossref","unstructured":"Tung H-Y, Su Y-C, Chen B-M, et al. Selective Delivery of PEGylated Compounds to Tumor Cells by Anti-PEG Hybrid Antibodies. Mol Cancer Ther; 14: 1317\u201326.","DOI":"10.1158\/1535-7163.MCT-15-0151"},{"key":"10.1016\/j.nano.2019.102076_bb0135","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s00259-014-2738-2","article-title":"Bispecific antibody complex pre-targeting and targeted delivery of polymer drug conjugates for imaging and therapy in dual human mammary cancer xenografts","volume":"41","author":"Khaw","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nano.2019.102076_bb0140","unstructured":"Goldenberg DM, Chatal J-F, Barbet J, et al. Cancer Imaging and Therapy with Bispecific Antibody Pretargeting"},{"key":"10.1016\/j.nano.2019.102076_bb0145","doi-asserted-by":"crossref","first-page":"5106","DOI":"10.7150\/thno.26585","article-title":"Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: curative treatment of HER2-positive breast carcinoma","volume":"8","author":"Cheal","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.nano.2019.102076_bb0150","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.2967\/jnumed.117.193250","article-title":"Curative multicycle radioimmunotherapy monitored by quantitative SPECT\/CT-based theranostics, using bispecific antibody pretargeting strategy in colorectal cancer","volume":"58","author":"Cheal","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nano.2019.102076_bb0155","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jconrel.2017.03.388","article-title":"Pretargeting with bispecific fusion proteins facilitates delivery of nanoparticles to tumor cells with distinct surface antigens","volume":"255","author":"Yang","year":"2017","journal-title":"J Control Release"},{"key":"10.1016\/j.nano.2019.102076_bb0160","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nbt.2797","article-title":"Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface","volume":"32","author":"Lewis","year":"2014","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.nano.2019.102076_bb0165","doi-asserted-by":"crossref","first-page":"11804","DOI":"10.1021\/acs.analchem.6b03437","article-title":"Analysis of pre-existing IgG and IgM antibodies against polyethylene glycol (PEG) in the general population","volume":"88","author":"Yang","year":"2016","journal-title":"Anal Chem"},{"key":"10.1016\/j.nano.2019.102076_bb0170","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1016\/j.nano.2019.102076_bb0175","unstructured":"Cheng TL, Roffler SR, Chuang KH, et al. Anti-polyethylene glycol antibody expressing cell quantify any free polyethylene glycol and polyethylene glycol-derivatized molecules. US Appl 20120015380A1 https:\/\/www.google.com\/patents\/US20120015380 (2012, accessed 18 July 2018)."},{"key":"10.1016\/j.nano.2019.102076_bb0180","unstructured":"Breece TN, Fahrner RL, Gorrell JR, et al. Protein Purification. Pat No US 6,870,034 B2, https:\/\/patents.google.com\/patent\/US6870034B2\/en (2005)."},{"key":"10.1016\/j.nano.2019.102076_bb0185","author":"Bleeker","year":"2001","journal-title":"Accelerated autoantibody clearance by intravenous immunoglobulin therapy: Studies in experimental models to determine the magnitude and time course of the effect Blood Epub ahead of print"},{"key":"10.1016\/j.nano.2019.102076_bb0190","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2174\/157015909790031166","article-title":"Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies","volume":"7","author":"Jacob","year":"2009","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.nano.2019.102076_bb0195","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000265166","article-title":"Doxorubicin cardiomyopathy","volume":"115","author":"Chatterjee","year":"2010","journal-title":"Cardiology"},{"key":"10.1016\/j.nano.2019.102076_bb0200","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/emmm.201201379","article-title":"Fc-fusion proteins: new developments and future perspectives","volume":"4","author":"Czajkowsky","year":"2012","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.nano.2019.102076_bb0205","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0958-1669(92)90164-E","article-title":"Fusion proteins in biotechnology","volume":"3","author":"Uhl\u00e9n","year":"1992","journal-title":"Curr Opin Biotechnol"},{"key":"10.1016\/j.nano.2019.102076_bb0210","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3109\/07388551.2016.1163323","article-title":"Fc\u03b31 fragment of IgG1 as a powerful affinity tag in recombinant fc-fusion proteins: immunological, biochemical and therapeutic properties","volume":"37","author":"Soleimanpour","year":"2017","journal-title":"Crit Rev Biotechnol"},{"key":"10.1016\/j.nano.2019.102076_bb0215","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.tibtech.2010.03.007","article-title":"Multivalent antibodies: When design surpasses evolution","volume":"28","author":"Cuesta","year":"2010","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.nano.2019.102076_bb0220","article-title":"ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy","volume":"7","author":"Harwood","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.nano.2019.102076_bb0225","unstructured":"Roffler SR. 6\u20133 high-affinity anti-PEG IgG monoclonal antibody, http:\/\/www.ibms.sinica.edu.tw\/~sroff\/anti-PEG\/6-3.html (2016)."},{"key":"10.1016\/j.nano.2019.102076_bb0230","doi-asserted-by":"crossref","first-page":"9930","DOI":"10.1016\/j.biomaterials.2014.08.032","article-title":"One-step mixing with humanized anti-mPEG bispecific antibody enhances tumor accumulation and therapeutic efficacy of mPEGylated nanoparticles","volume":"35","author":"Kao","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.nano.2019.102076_bb0235","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1080\/10717544.2018.1466936","article-title":"Bispecific antibodies (anti-mPEG\/anti-HER2) for active tumor targeting of docetaxel (DTX)-loaded mPEGylated nanocarriers to enhance the chemotherapeutic efficacy of HER2-overexpressing tumors","volume":"25","author":"Su","year":"2018","journal-title":"Drug Deliv"},{"key":"10.1016\/j.nano.2019.102076_bb0240","doi-asserted-by":"crossref","first-page":"360","DOI":"10.7150\/ntno.27142","article-title":"In vivo therapeutic evaluation of polymeric nanomedicines: effect of different targeting peptides on therapeutic efficacy against breast cancer","volume":"2","author":"Zhao","year":"2018","journal-title":"Nanotheranostics"},{"key":"10.1016\/j.nano.2019.102076_bb0245","doi-asserted-by":"crossref","first-page":"1801607","DOI":"10.1002\/adhm.201801607","article-title":"Modulating targeting of poly(ethylene glycol) particles to tumor cells using bispecific antibodies","volume":"1801607","author":"Cui","year":"2019","journal-title":"Adv Healthc Mater"},{"key":"10.1016\/j.nano.2019.102076_bb0250","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejps.2016.03.009","article-title":"Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model","volume":"86","author":"Zahmatkeshan","year":"2016","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.nano.2019.102076_bb0255","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1016\/j.nucmedbio.2013.12.012","article-title":"Influence of pegylation and hapten location at the surface of radiolabelled liposomes on tumour immunotargeting using bispecific antibody","volume":"41","author":"Rauscher","year":"2014","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nano.2019.102076_bb0260","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3389\/fmed.2015.00083","article-title":"Improvement of the targeting of radiolabeled and functionalized liposomes with a two-step system using a bispecific monoclonal antibody (Anti-CEA \u00d7 Anti-DTPA\u2013In)","volume":"2","author":"Rauscher","year":"2015","journal-title":"Front Med"},{"key":"10.1016\/j.nano.2019.102076_bb0265","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.biomaterials.2019.02.012","article-title":"Site-specific conjugation of recognition tags to trastuzumab for peptide nucleic acid-mediated radionuclide HER2 pretargeting","volume":"203","author":"Westerlund","year":"2019","journal-title":"Biomaterials"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963419301601?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963419301601?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:13:20Z","timestamp":1761549200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963419301601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":53,"alternative-id":["S1549963419301601"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2019.102076","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pretargeted delivery of PEG-coated drug carriers to breast tumors using multivalent, bispecific antibody against polyethylene glycol and HER2","name":"articletitle","label":"Article Title"},{"value":"Nanomedicine: Nanotechnology, Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nano.2019.102076","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102076"}}